Simon GUIGNARD

Mr. Simon GUIGNARD

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 May 2020 in Nutrients
Verified
Journal Article
Open access
PDF file
MFMorgane Frapin
Morgane Frapin
SGSimon GUIGNARD
Simon GUIGNARD
DMDimitri Meistermann
Dimitri Meistermann
IGIsabelle Grit
Isabelle Grit
VMValentine Moullé
Valentine Moullé
VAValerie Amarger
Valerie Amarger
Fetal brain development is closely dependent on maternal nutrition and metabolic status. Maternal protein restriction (PR) is known to be associated with alterations in the structure and function of the hypothalamus, leading to impaired control of energy homeostasis and food intake. The objective of this study was to identify the cellular and molecular systems underlying these effects during fetal development. We combined a global transcriptomic analysis on the fetal hypothalamus from a rat model of maternal PR with in vitro neurosphere culture and cellular analyses. Several genes encoding proteins from the mitochondrial respiratory chain complexes were overexpressed in the PR group and mitochondrial metabolic activity in the fetal hypothalamus was altered. The level of the N6-methyladenosine epitranscriptomic mark was reduced in the PR fetuses, and the expression of several genes involved in the writing/erasing/reading of this mark was indeed altered, as well as genes encoding several RNA-binding proteins. Additionally, we observed a higher number of neuronal-committed progenitors at embryonic day 17 (E17) in the PR fetuses. Together, these data strongly suggest a metabolic adaptation to the amino acid shortage, combined with the post-transcriptional control of protein expression, which might reflect alterations in the control of the timing of neuronal progenitor differentiation.

11 March 2025 in Journal of Lipid Research
Verified
Journal Article
Open access
SGSilvia Gonzalez-Nieves
Silvia Gonzalez-Nieves
XWXiaochao Wei
Xiaochao Wei
SGSimon GUIGNARD
Simon GUIGNARD
TNThi Nguyen
Thi Nguyen
JMJay McQuillan
Jay McQuillan
VCVincenza Cifarelli
Vincenza Cifarelli
Lipid metabolism plays a critical role in lymphatic endothelial cell (LEC) development and vessel maintenance. Altered lipid metabolism is associated with loss of lymphatic vessel integrity, which compromises organ function, protective immunity, and metabolic health. Thus, understanding how lipid metabolism affects LECs is critical for uncovering the mechanisms underlying lymphatic dysfunction. Protein palmitoylation, a lipid-based post-translational modification, has emerged as a critical regulator of protein function, stability, and interaction networks. Insulin, a master regulator of systemic lipid metabolism, also regulates protein palmitoylation. However, the role of insulin-driven palmitoylation in LEC biology remains unexplored. To examine the role of palmitoylation in LEC function, we generated the first palmitoylation proteomics profile in human LECs, validated insulin-regulated targets, and determined the role of palmitoylation in LEC barrier function. In unstimulated conditions, palmitoylation occurred primarily on proteins involved in vesicular and membrane trafficking, and in translation initiation. Insulin treatment, instead, enriched palmitoylation of proteins involved in LEC integrity, namely junctional proteins such as claudin 5, along with small GTPases and ubiquitination enzymes. We also investigated the role of the long-chain fatty acid transporter CD36, a major mediator of palmitate uptake into cells, in regulating optimal lymphatic protein palmitoylation. CD36 silencing in LECs increased by 2-fold palmitoylation of proteins involved in inflammation and immune cell activation. Overall, our findings provide novel insights into the intricate relationship between lipid modification and LEC function, suggesting that insulin and palmitoylation play a critical role in lymphatic endothelial function.

3 January 2026 in bioRxiv
Verified
Preprint
Open access
SGSimon GUIGNARD
Simon GUIGNARD
MCMolee Chakraborty
Molee Chakraborty
SGSilvia Gonzalez-Nieves
Silvia Gonzalez-Nieves
DDDavid Debruin
David Debruin
EEEmily Ebert
Emily Ebert
VCVincenza Cifarelli
Vincenza Cifarelli
Background: Ubiquitin-dependent signaling is essential for maintaining intestinal homeostasis and its dysregulation contributes to chronic intestinal disorders, such as Inflammatory Bowel Disease (IBD). Ube4A is a U-box E3/E4 ubiquitin ligase involved in lipid metabolism and insulin signaling in metabolic tissues. Autoantibodies against Ube4A have been identified in patients with IBD and are associated with disease long-term complications. Despite these clinical associations, the physiological role of Ube4A in the gastrointestinal tract remains unknown. This study aimed to define the function of Ube4A in the colon and determine how its loss influences susceptibility to experimental colitis. Methods: UBE4A expression in human colonic tissue from healthy individuals and patients with IBD was analyzed using publicly available single-cell RNA sequencing datasets. The role of Ube4A in colonic homeostasis and colitis pathogenesis was examined using global Ube4A knockout (UKO) mice subjected to dextran sulfate sodium (DSS)-induced colitis. UKO colon phenotypes were characterized using transcriptomic analyses, immunofluorescence, and flow cytometry. Results: UBE4A is highly expressed in human colonic epithelial cells, and its expression is reduced from healthy to IBD inflamed tissues. In mice, Ube4A deficiency significantly exacerbated DSS-induced colitis, as evidenced by increased weight loss, disease activity scores, shortened colon length, and more severe histological injury. Transcriptomic profiling revealed enhanced inflammatory signaling, alongside dysregulation of lipid transport and storage, as well as antimicrobial defense pathways. DSS-treated UKO mice also exhibited increased mast cell activation and elevated expression of matrix metalloproteinases. Importantly, colons from UKO mice displayed baseline transcriptional alterations indicative of epithelial stress and disrupted lipid metabolic programs, even in the absence of injury. Conclusions: Ube4A is a previously unrecognized regulator of colon homeostasis. Its loss induces existing epithelial stress and metabolic reprogramming that sensitize the colon to exaggerated inflammatory responses during injury such as experimental colitis.

16 October 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
YJYiping Jia
Yiping Jia
SGSilvia Gonzalez-Nieves
Silvia Gonzalez-Nieves
SGSimon GUIGNARD
Simon GUIGNARD
VCVincenza Cifarelli
Vincenza Cifarelli
SFStacey D Finley
Stacey D Finley
Lymphatic endothelial cell (LEC) junctions switch between continuous zippers and discontinuous buttons to control fluid, cell and lipid uptake, but how the strength and timing of signaling set junction state is unknown. Here we present, to our knowledge, the first mechanistic signaling model calibrated to LEC data, linking VEGF-A-induced activation of VEGFR2 homodimers and VEGFR2/VEGFR3 heterodimers to the balance of active RAC1 and RhoA, summarized as a predicted zippering propensity. Calibrated to human dermal LEC time courses and validated against independent receptor knockdowns, the model predicts that VEGF-A dose primarily determines how long zippering-favoring signaling lasts following stimulation, and it identifies which of the parameters related to RAC1-RhoA kinetics control this duration. Using single-cell transcriptomes from high-fat-diet-fed mice, the model predicts that obesity shortens this response in mesenteric capillary and epididymal collector LECs but prolongs it in epididymal capillary LECs. Tuning RAC1–RhoA kinetics restores baseline in each population but requires opposite adjustments, suggesting that targeting this axis must be context-specific.

8 April 2026
Verified
Thesis
Closed access
SGSimon GUIGNARD
Simon GUIGNARD
L'épithélium intestinal est exposé à un grand nombre d'enzymes protéolytiques pouvant provenir des sécrétions pancréatiques, du microbiote ou de la muqueuse de l'hôte. Plus que de simples enzymes cataboliques, les protéases jouent un rôle clé dans le maintien de l'homéostasie intestinale en assurant des fonctions très variées. Certaines d'entre elles sont notamment capables d'activer une famille de récepteurs membranaires : les Récepteurs Activés par les Protéases (PARs), qui comprennent 4 membres (PAR1-4). Ils sont exprimés par de nombreux types cellulaires dans l'intestin, y compris les cellules épithéliales, et ont des effets pléiotropes. Une connaissance fine des acteurs de la signalisation protéolytique est donc un enjeu majeur pour mieux comprendre la physiologie intestinale. Les travaux conduits au cours de cette thèse se sont attachés à caractériser le rôle de la chymotrypsine, une protéase pancréatique essentiellement connue pour son rôle digestif, dans l'homéostasie intestinale. Abondamment déversée dans la lumière intestinale, nous avons pu montrer que la chymotrypsine était retrouvée sous sa forme active à proximité de la muqueuse intestinale. Nous avons ensuite caractérisé les effets potentiels de cette protéase sur l'épithélium intestinal, notamment via l'activation des récepteurs PARs. Par des approches pharmacologiques, nous avons mis en évidence que cette enzyme était capable de cliver les récepteurs PAR1 et PAR2, tous deux exprimés par les cellules épithéliales intestinales. Dans des lignées cellulaires, mes travaux ont montré que cette enzyme activait le récepteur PAR2, induisant l'activation d'une signalisation calcique et MAPK intracellulaire. En revanche, elle désarme PAR1, prévenant ainsi son activation par son agoniste canonique, la thrombine. Nous avons ensuite étudié les effets fonctionnels de la chymotrypsine sur l'épithélium intestinal in vitro. Le traitement d'organoïdes coliques humains avec de la chymotrypsine promeut l'expression de gènes importants pour le maintien de l'homéostasie épithéliale (IL10, MUC2, LGR5, CHGA), sans modifier l'expression de facteurs pro-inflammatoires. Ceci suggère un effet protecteur de cette enzyme vis-à-vis de l'épithélium intestinal. De plus, l'induction de l'expression d'IL10 par la chymotrypsine semble dépendante du récepteur PAR2, indiquant des effets fonctionnels de l'axe chymotrypsine-PAR2. En outre, plusieurs études indiquent que la suractivation de certaines protéases contribue à la physiopathologie des Maladies Inflammatoires Chroniques de l'Intestin (MICI). Nous avons donc exploré la régulation de cette enzyme en contexte d'inflammation intestinale. Dans une cohorte humaine, nous avons observé que l'activité chymotrypsique fécale était significativement augmentée chez des patients atteints de MICI, comparée à des donneurs sains. Cette augmentation était spécifiquement retrouvée chez des patients dont la maladie était cliniquement active. Ces investigations préliminaires ouvrent la voie à des études plus poussées permettant d'explorer précisément le rôle de cette protéase en condition pathologique. En parallèle, nous avons également recherché une potentielle expression extra-pancréatique de la chymotrypsine, par la muqueuse digestive. Chez L'Homme et la souris, nos analyses ont montré que certaines formes de chymotrypsine étaient détectées dans l'épithélium intestinal mais aussi gastrique, ouvrant de nouvelles perspectives sur les fonctions de cette enzyme au sein de ces tissus. En conclusion, ces travaux de thèse ont permis d'identifier la chymotrypsine comme un nouvel acteur de la signalisation protéolytique dans le tractus digestif dont les fonctions vont bien au-delà de ses seules implications digestives. Additionnés à la littérature existante, nos résultats apportent un nouvel éclairage sur l'importance des protéases luminales dans les interactions complexes qui régissent l'homéostasie intestinale.